TORNTPHARM — Torrent Pharmaceuticals Share Price
Last trade - 00:00- IN₹1.61tn
- IN₹1.83tn
- IN₹139.80bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 58.1 | ||
| PEG Ratio (f) | 3.5 | ||
| EPS Growth (f) | 19.93% | ||
| Dividend Yield (f) | 0.57% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.22 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 68.73 | ||
| Price to Sales | 11.53 | ||
| EV to EBITDA | 40.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.32% | ||
| Return on Equity | 27.08% | ||
| Operating Margin | 23.97% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 85,080.4 | 96,201.5 | 107,278.4 | 115,160.9 | 139,797.3 | 181,338.34 | 203,960.26 | 11.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -13.39 | +13.75 | +29.95 | +20.23 | +14.98 | +14.68 | +30.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company focuses on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), women healthcare (WHC), Vitamins Minerals & Nutrients (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynecology, oncology and anti-infective segments. Its brands include Ahaglow, Shelcal, Tedibar, and Unienzyme. Its tedibar brands include Tedibar bathing bar, Tedibar Atogla, Tedibar Spoo and Tedibar B4 Nappi. Its Shelcal includes Shelcal 500, Shelcal Pro Gummies, Kids Gummies, and Shelcal Total. The Company's manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
Directors
- Samir Mehta CHM (58)
- Sudhir Mehta NEC (67)
- Sudhir Menon CFO
- Mahesh Agrawal VPR
- Jinesh Shah EDR
- Nayantara Bali IND
- Shailesh Haribhakti IND (65)
- Haigreve Khaitan IND (51)
- Ameera Shah IND
- Last Annual
- March 31st, 2026
- Last Interim
- March 31st, 2026
- Incorporated
- July 15th, 1972
- Public Since
- November 3rd, 1994
- No. of Shareholders
- 85,781
- No. of Employees
- 17,729
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 338,445,440
- Address
- Avirat, Thaltej Shilaj Road, AHMEDABAD, 380059
- Web
- https://www.torrentpharma.com/
- Phone
- +91 7926599000
- Contact
- Chintan Trivedi
- Auditors
- BSR & Co. LLP
Latest News for TORNTPHARM
Upcoming Events for TORNTPHARM
Q1 2027 Torrent Pharmaceuticals Ltd Earnings Release
Q2 2027 Torrent Pharmaceuticals Ltd Earnings Release
Similar to TORNTPHARM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 23:46 UTC, shares in Torrent Pharmaceuticals are trading at IN₹4,763.00. This share price information is delayed by 15 minutes.
Shares in Torrent Pharmaceuticals last closed at IN₹4,763.00 and the price had moved by +35.91% over the past 365 days. In terms of relative price strength the Torrent Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +38.58% over the past year.
The overall consensus recommendation for Torrent Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Torrent Pharmaceuticals dividend yield is 0.8% based on the trailing twelve month period.
Last year, Torrent Pharmaceuticals paid a total dividend of IN₹38.00, and it currently has a trailing dividend yield of 0.8%. We do not have any data on when Torrent Pharmaceuticals is to next pay dividends.
We do not have data on when Torrent Pharmaceuticals is to next pay dividends. The historic dividend yield on Torrent Pharmaceuticals shares is currently 0.8%.
To buy shares in Torrent Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹4,763.00, shares in Torrent Pharmaceuticals had a market capitalisation of IN₹1.61tn.
Here are the trading details for Torrent Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: TORNTPHARM
Based on an overall assessment of its quality, value and momentum Torrent Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Torrent Pharmaceuticals is IN₹4,816.90. That is 1.13% above the last closing price of IN₹4,763.00.
Analysts covering Torrent Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹75.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Torrent Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +23.02%.
As of the last closing price of IN₹4,763.00, shares in Torrent Pharmaceuticals were trading +16.31% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Torrent Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 58.1. The shares last closed at IN₹4,763.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Torrent Pharmaceuticals' management team is headed by:
- Samir Mehta - CHM
- Sudhir Mehta - NEC
- Sudhir Menon - CFO
- Mahesh Agrawal - VPR
- Jinesh Shah - EDR
- Nayantara Bali - IND
- Shailesh Haribhakti - IND
- Haigreve Khaitan - IND
- Ameera Shah - IND